Pegaspargase (PEG) Asparaginase

DRUG3 trials

Sponsors

Sanofi, Beijing Tongren Hospital

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaExtranodal NK T Cell LymphomaExtranodal NK/T-cell LymphomaHemophagocytic Lymphohistiocytosis (HLH)

Phase 1

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

RecruitingNCT07525466

Beijing Tongren HospitalExtranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)

Start: 2026-04-01End: 2028-09-30Target: 25Updated: 2026-04-13

Phase 2

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

TerminatedNCT03860844

SanofiAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2019-08-06End: 2023-05-26Updated: 2025-09-09

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Not yet recruitingNCT07554482

Beijing Tongren HospitalExtranodal NK/T-cell Lymphoma

Start: 2026-05-15End: 2029-04-30Target: 34Updated: 2026-04-28

Related Papers

Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics.

2025-12-03

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study.

2025-10-30

P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS

HemaSphere2023-08-014 citations

Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis

Blood2021-11-0510 citations